Neuronetics projects FY25 revenue between $147M and $150M, below consensus estimate of $151.03M.
Revenue Expectations: The company anticipates total worldwide revenue for 2025 to be between $147 million and $150 million, a decrease from previous guidance of $149 million to $155 million.
Gross Margin Forecast: The expected gross margin for 2025 is now projected to be between 47% and 49%, down from the earlier estimate of 48% to 50%.
Operating Expenses: The company continues to expect total operating expenses for 2025 to remain between $100 million and $105 million.
Cash Flow Projections: The company aims for positive cash flow from operations in Q4 2025, with a range of $2 million positive to $2 million negative, and projects year-end total cash to be between $32 million and $36 million.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on STIM
About STIM
About the author
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.
TRICARE West Broadens NeuroStar® TMS Coverage to Support Adolescents 15 and Older Facing Depression
TRICARE Coverage Expansion: Neuronetics, Inc. announced that TriWest has updated its medical policy to include TMS coverage for adolescents aged 15 and older, benefiting military families in multiple states.
Significance of TMS for Adolescents: The expansion of TMS coverage is seen as a crucial step in providing effective treatment for adolescents struggling with depression, especially given the limited medication options available.
NeuroStar's Unique Position: NeuroStar is the first TMS company with FDA clearance for adolescent treatment and has a dedicated health policy team advocating for further access to TMS therapy.
Impact on Mental Health: With an estimated 4.3 million U.S. adolescents affected by major depression, NeuroStar Advanced Therapy offers a non-invasive treatment option that can significantly improve quality of life when traditional medications fail.
Neuronetics Releases Financial and Operational Results for Q3 2025 and Unveils CEO Transition Strategy
Financial Performance: Neuronetics reported Q3 2025 revenue of $37.3 million, an 11% increase on an adjusted pro forma basis compared to Q3 2024, with significant growth in Greenbrook clinic revenue, which reached $21.8 million, a 25% increase year-over-year.
Operational Highlights: The company achieved over 229,429 global patients treated and received $10 million in additional funding under a debt agreement, while New York State Medicaid expanded coverage for TMS therapy, enhancing access for over 5 million members.
Leadership Transition: CEO Keith J. Sullivan announced his intention to retire on June 30, 2026, after five years of leadership, during which he played a key role in the strategic acquisition of Greenbrook TMS.
Future Outlook: Neuronetics anticipates Q4 2025 revenue between $40 million and $43 million, with a target for positive cash flow from operations, while adjusting full-year revenue expectations to between $147 million and $150 million.
Neuronetics, Inc. Reports Reduced Q3 Loss, Falls Short of Expectations
Earnings Report: Neuronetics, Inc. reported a loss of -$9.05 million for the third quarter, an improvement from -$13.34 million the previous year, but it missed analysts' expectations of -$0.12 per share.
Revenue Growth: The company's revenue increased by 101.3% to $37.30 million, up from $18.53 million in the same quarter last year.
Earnings Per Share: The earnings per share (EPS) for the quarter was -$0.13, compared to -$0.44 in the prior year.
Future Guidance: Neuronetics provided full-year revenue guidance of $147 million to $150 million.
Neuronetics Forms Exclusive Three-Year Partnership with Elite DNA Behavioral Health to Enhance NeuroStar Availability and Operational Efficiency
Exclusive Partnership Announcement: Neuronetics, Inc. has entered a three-year exclusive agreement with Elite DNA Behavioral Health to provide transcranial magnetic stimulation (TMS) devices across over 30 locations in Florida, enhancing access to mental health treatment.
Enhanced Patient Support Services: The collaboration will also include expanded operational and patient-support services, allowing Elite DNA to focus on improving patient experiences while utilizing Neuronetics' Greenbrook platform.
Commitment to Mental Health Care: Both companies emphasize their shared mission to improve access to comprehensive mental health care, ensuring timely and coordinated treatment for patients suffering from severe depression.
Future Expansion Plans: The partnership is set to pilot in late 2025, with plans for further expansion in 2026, aiming to operationalize a scalable model of care for other organizations in the future.
Neuronetics to Announce Financial and Operational Results for Q3 2025 and Conduct Conference Call
Upcoming Financial Results: Neuronetics, Inc. will release its third quarter 2025 financial and operating results on November 4, 2025, and will host a conference call at 8:30 a.m. Eastern Time to discuss these results.
Company Overview: Neuronetics is a leader in neurohealth technology, known for its NeuroStar® Advanced Therapy, a non-invasive treatment for major depressive disorder (MDD) and other mental health conditions, with over 7.6 million treatments delivered.
Treatment Centers: The company operates Greenbrook TMS Inc. treatment centers across the U.S., providing NeuroStar Advanced Therapy and SPRAVATO® (esketamine) Nasal Spray for treatment-resistant depression and other related conditions.
FDA Clearance: The NeuroStar Advanced Therapy System is FDA-cleared for various uses, including treatment of MDD in adults and adolescents, and for patients with comorbid anxiety symptoms, highlighting its broad applicability in mental health treatment.
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Oversold Stocks in Health Care: The health care sector has several oversold stocks, presenting potential buying opportunities for undervalued companies, particularly those with a Relative Strength Index (RSI) below 30.
Inotiv Inc Performance: Inotiv Inc reported strong contract awards and anticipates fourth-quarter revenue between $137.5 million and $138.5 million, despite its stock falling 38% recently, with an RSI of 26.7.
Airsculpt Technologies Update: Airsculpt Technologies faced disappointing third-quarter results and lowered its FY25 revenue outlook, leading to a 60% stock drop over the past month, with an RSI of 29.3.
Neuronetics Sales Guidance: Neuronetics cut its FY2025 sales guidance, resulting in a 40% decline in stock value over the past month, and it currently has an RSI of 23.9.
TRICARE West Broadens NeuroStar® TMS Coverage to Support Adolescents 15 and Older Facing Depression
TRICARE Coverage Expansion: Neuronetics, Inc. announced that TriWest has updated its medical policy to include TMS coverage for adolescents aged 15 and older, benefiting military families in multiple states.
Significance of TMS for Adolescents: The expansion of TMS coverage is seen as a crucial step in providing effective treatment for adolescents struggling with depression, especially given the limited medication options available.
NeuroStar's Unique Position: NeuroStar is the first TMS company with FDA clearance for adolescent treatment and has a dedicated health policy team advocating for further access to TMS therapy.
Impact on Mental Health: With an estimated 4.3 million U.S. adolescents affected by major depression, NeuroStar Advanced Therapy offers a non-invasive treatment option that can significantly improve quality of life when traditional medications fail.
Neuronetics Releases Financial and Operational Results for Q3 2025 and Unveils CEO Transition Strategy
Financial Performance: Neuronetics reported Q3 2025 revenue of $37.3 million, an 11% increase on an adjusted pro forma basis compared to Q3 2024, with significant growth in Greenbrook clinic revenue, which reached $21.8 million, a 25% increase year-over-year.
Operational Highlights: The company achieved over 229,429 global patients treated and received $10 million in additional funding under a debt agreement, while New York State Medicaid expanded coverage for TMS therapy, enhancing access for over 5 million members.
Leadership Transition: CEO Keith J. Sullivan announced his intention to retire on June 30, 2026, after five years of leadership, during which he played a key role in the strategic acquisition of Greenbrook TMS.
Future Outlook: Neuronetics anticipates Q4 2025 revenue between $40 million and $43 million, with a target for positive cash flow from operations, while adjusting full-year revenue expectations to between $147 million and $150 million.
Neuronetics, Inc. Reports Reduced Q3 Loss, Falls Short of Expectations
Earnings Report: Neuronetics, Inc. reported a loss of -$9.05 million for the third quarter, an improvement from -$13.34 million the previous year, but it missed analysts' expectations of -$0.12 per share.
Revenue Growth: The company's revenue increased by 101.3% to $37.30 million, up from $18.53 million in the same quarter last year.
Earnings Per Share: The earnings per share (EPS) for the quarter was -$0.13, compared to -$0.44 in the prior year.
Future Guidance: Neuronetics provided full-year revenue guidance of $147 million to $150 million.
Neuronetics Forms Exclusive Three-Year Partnership with Elite DNA Behavioral Health to Enhance NeuroStar Availability and Operational Efficiency
Exclusive Partnership Announcement: Neuronetics, Inc. has entered a three-year exclusive agreement with Elite DNA Behavioral Health to provide transcranial magnetic stimulation (TMS) devices across over 30 locations in Florida, enhancing access to mental health treatment.
Enhanced Patient Support Services: The collaboration will also include expanded operational and patient-support services, allowing Elite DNA to focus on improving patient experiences while utilizing Neuronetics' Greenbrook platform.
Commitment to Mental Health Care: Both companies emphasize their shared mission to improve access to comprehensive mental health care, ensuring timely and coordinated treatment for patients suffering from severe depression.
Future Expansion Plans: The partnership is set to pilot in late 2025, with plans for further expansion in 2026, aiming to operationalize a scalable model of care for other organizations in the future.
Neuronetics to Announce Financial and Operational Results for Q3 2025 and Conduct Conference Call
Upcoming Financial Results: Neuronetics, Inc. will release its third quarter 2025 financial and operating results on November 4, 2025, and will host a conference call at 8:30 a.m. Eastern Time to discuss these results.
Company Overview: Neuronetics is a leader in neurohealth technology, known for its NeuroStar® Advanced Therapy, a non-invasive treatment for major depressive disorder (MDD) and other mental health conditions, with over 7.6 million treatments delivered.
Treatment Centers: The company operates Greenbrook TMS Inc. treatment centers across the U.S., providing NeuroStar Advanced Therapy and SPRAVATO® (esketamine) Nasal Spray for treatment-resistant depression and other related conditions.
FDA Clearance: The NeuroStar Advanced Therapy System is FDA-cleared for various uses, including treatment of MDD in adults and adolescents, and for patients with comorbid anxiety symptoms, highlighting its broad applicability in mental health treatment.
